Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1533

1.

Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases.

Němejcová K, Cibula D, Dundr P.

Diagn Pathol. 2015 Mar 25;10(1):8. [Epub ahead of print]

2.

The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.

Suh DH, Park JY, Lee JY, Kim BG, Lim MC, Kim JW, Bae DS, Park SY, Nam JH, Kim K, No JH, Kim YB.

Gynecol Oncol. 2015 Apr 11. pii: S0090-8258(15)00789-1. doi: 10.1016/j.ygyno.2015.03.058. [Epub ahead of print]

PMID:
25868967
3.

The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.

Kucukgoz Gulec U, Paydas S, Guzel AB, Vardar MA, Khatib G, Gumurdulu D.

Arch Gynecol Obstet. 2015 Apr 9. [Epub ahead of print]

PMID:
25855053
4.

Body fatness, related biomarkers and cancer risk: an epidemiological perspective.

Nimptsch K, Pischon T.

Horm Mol Biol Clin Investig. 2015 Mar 14. pii: /j/hmbci.ahead-of-print/hmbci-2014-0043/hmbci-2014-0043.xml. doi: 10.1515/hmbci-2014-0043. [Epub ahead of print]

PMID:
25781710
5.

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study.

Kim HS, Choi HY, Lee M, Suh DH, Kim K, No JH, Chung HH, Kim YB, Song YS.

Cancer Res Treat. 2015 Mar 6. doi: 10.4143/crt.2014.324. [Epub ahead of print]

PMID:
25761476
Free Article
6.

Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Chen CA, Chiang YC, Chang MC, Hu YH, You SL, Cheng YY, Chou CY, Cheng WF.

Am J Transl Res. 2015 Jan 15;7(1):139-52. eCollection 2015.

7.

Ovarian Seromucinous Carcinoma: Report of a Series of a Newly Categorized and Uncommon Neoplasm.

Taylor J, McCluggage WG.

Am J Surg Pathol. 2015 Feb 26. [Epub ahead of print]

PMID:
25723110
8.

Primary peritoneal clear cell carcinoma versus ovarian carcinoma versus malignant transformation of endometriosis: a vexing issue.

Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S.

Int J Surg Pathol. 2015 May;23(3):211-6. doi: 10.1177/1066896915573567. Epub 2015 Feb 24.

PMID:
25715342
9.

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.

Mabuchi S, Kuroda H, Takahashi R, Sasano T.

Gynecol Oncol. 2015 Apr;137(1):173-179. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10. Review.

PMID:
25677064
10.

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M.

PLoS One. 2015 Feb 6;10(2):e0116977. doi: 10.1371/journal.pone.0116977. eCollection 2015.

11.

Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.

Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.

Int J Oncol. 2015 Apr;46(4):1573-81. doi: 10.3892/ijo.2015.2858. Epub 2015 Jan 28.

PMID:
25633807
12.

Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.

Pamuła-Piłat J, Rubel T, Rzepecka IK, Olbryt M, Herok R, Dansonka-Mieszkowska A, Grzybowska E, Kupryjańczyk J.

J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):659-74.

PMID:
25620176
13.

Epigenetic and genetic dispositions of ovarian carcinomas.

Yamaguchi K, Matsumura N, Mandai M, Baba T, Konishi I, Murphy SK.

Oncoscience. 2014 Sep 22;1(9):574-9. eCollection 2014.

14.

Clear cell carcinoma derived from an endometriosis focus in a scar after a caesarean section--a case report and literature review.

Dobrosz Z, Paleń P, Stojko R, Właszczuk P, Niesłuchowska-Hoxha A, Piechuta-Kośmider I.

Ginekol Pol. 2014 Oct;85(10):792-5. Review.

PMID:
25546933
15.

Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.

Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.

Mol Cancer Res. 2015 Apr;13(4):795-806. doi: 10.1158/1541-7786.MCR-14-0314. Epub 2014 Dec 17.

PMID:
25519148
16.

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.

Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK.

Gynecol Oncol. 2015 Feb;136(2):198-204. doi: 10.1016/j.ygyno.2014.12.006. Epub 2014 Dec 10.

PMID:
25497604
17.

[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].

Konishi H, Takehara K, Okame S, Yamamoto Y, Kojima A, Shiroyama Y, Yokoyama T, Nogawa T.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1437-9. Japanese.

PMID:
25434451
18.

Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Matsuo Y, Tashiro H, Yanai H, Moriya T, Katabuchi H.

Med Mol Morphol. 2014 Nov 15. [Epub ahead of print]

PMID:
25398420
19.

The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary.

Kandalaft PL, Gown AM, Isacson C.

Am J Clin Pathol. 2014 Dec;142(6):830-6. doi: 10.1309/AJCP8WO2EOIAHSOF.

PMID:
25389337
20.

Napsin A: Another milestone in the subclassification of ovarian carcinoma.

Köbel M, Duggan MA.

Am J Clin Pathol. 2014 Dec;142(6):735-7. doi: 10.1309/AJCPAVGZKA1A1HVC. No abstract available.

PMID:
25389324
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk